Escherichia coli Nissle 1917 Targets and Restrains Mouse B16 Melanoma and 4T1 Breast Tumors through Expression of Azurin Protein
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
Many studies have demonstrated that intravenously administered bacteria can target and proliferate in solid tumors and then quickly be released from other organs. Here, we employed the tumor-targeting property of Escherichia coli Nissle 1917 to inhibit mouse B16 melanoma and 4T1 breast tumors through the expression of azurin protein. For this purpose, recombinant azurin-expressing E. coli Nissle 1917 was developed. The levels of in vitro and in vivo azurin secretion in the engineered bacterium were determined by immunochemistry. Our results demonstrated that B16 melanoma and orthotopic 4T1 breast tumor growth were remarkably restrained and pulmonary metastasis was prevented in immunocompetent mice. It is worth noting that this therapeutic effect partially resulted from the antitumor activity of neutrophils and lymphocytes due to inflammatory responses caused by bacterial infections. No toxicity was observed in the animal during the experiments. This study indicates that E. coli Nissle 1917 could be a potential carrier to deliver antitumor drugs effectively for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, E. coli has been shown to colonize the region surrounding the necrotic core of tumors after intravenous injection9, and several reports have demonstrated the use of engineered E. coli strains to treat solid tumors in preclinical models15,62–65.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [63]
In the citing paper
“Zhang et al. developed a strain of EcN to express azurin, a small bacterial protein that induces apoptosis in tumor cells62. This engineered strain suppressed the growth of tumors and prevented pulmonary metastasis in mice63.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Probiotics, Prebiotics, and Synbiotics
de Vrese, M., & Schrezenmeir, J. (2008) · Advances in Biochemical Engineering/Biotechnology · doi:10.1007/10_2008_097 · Cited by 1,028
Toso, J. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.142 · Cited by 614
Coley's toxins, tumor necrosis factor and cancer research: A historical perspective
Wiemann, B., & Starnes, C. O. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90023-x · Cited by 467
Probiotics, Prebiotics and Synbiotics
Hawrelak, J. (2007) · eCite Digital Repository (University of Tasmania) · Cited by 320
Zhao, M., Yang, M., Ma, H., Li, X., Tan, X., Li, S., Yang, Z., & Hoffman, R. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0716 · Cited by 305
Bacteriolytic therapy can generate a potent immune response against experimental tumors
Agrawal, N., Bettegowda, C., Cheong, I., Geschwind, J.-F., Drake, C. G., Hipkiss, E. L., Tatsumi, M., Dang, L. H., Diaz, L. A., Pomper, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406242101 · Cited by 304
Short hairpin RNA–expressing bacteria elicit RNA interference in mammals
Xiang, S., Fruehauf, J., & Li, C. J. (2006) · Nature Biotechnology · doi:10.1038/nbt1211 · Cited by 271
Stritzker, J., Weibel, S., Hill, P. J., Oelschlaeger, T. A., Goebel, W., & Szalay, A. A. (2007) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2007.01.008 · Cited by 224
Henker, J., Laass, M., Blokhin, B. M., Bolbot, Y. K., Maydannik, V. G., Elze, M., Wolff, C., & Schulze, J. (2007) · European Journal of Pediatrics · doi:10.1007/s00431-007-0419-x · Cited by 199
Noncationic Peptides Obtained From Azurin Preferentially Enter Cancer Cells
Taylor, B. N., Mehta, R. R., Yamada, T., Lekmine, F., Christov, K., Chakrabarty, A. M., Green, A., Bratescu, L., Shilkaitis, A., Beattie, C. W., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2932 · Cited by 184
Cited by
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0876 · Cited by 647
Developing a new class of engineered live bacterial therapeutics to treat human diseases
Charbonneau, M. R., Isabella, V. M., Li, N., & Kurtz, C. B. (2020) · Nature Communications · doi:10.1038/s41467-020-15508-1 · Cited by 523
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
Leventhal, D. S., Sokolovska, A., Li, N., Plescia, C., Kolodziej, S. A., Gallant, C. W., Christmas, R., Gao, J.-R., James, M. J., Abin-Fuentes, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16602-0 · Cited by 458
Fan, J.-X., Li, Z.-H., Liu, X.-H., Zheng, D.-W., Chen, Y., & Zhang, X.-Z. (2018) · Nano Letters · doi:10.1021/acs.nanolett.7b05323 · Cited by 264
Self-citation
Metadata
- Authors
- Zhang, Y., Zhang, Y., Xia, L., Zhang, X., Ding, X., Yan, F., & Wu, F.
- Affiliations
- Hunan Normal University (CN)
- College of Life Science, Hunan Provincial Key Laboratory of Microbial Molecular Biology—State Key Laboratory Breeding Base of Microbial Molecular Biology, Hunan Normal University, Changsha, China
- Venue
- Applied and Environmental Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2012-11
- Volume
- 78
- Issue
- 21
- Pages
- 7603-7610
- ISSN
- 0099-2240 (ISSN-L)
- 1098-5336
- PMC
- PMC3485711
- OpenAlex
- W1964108510
- Cited by
- 138
- References
- 46
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 14 · 2023: 12 · 2022: 16 · 2021: 15 · 2020: 18 · 2019: 6 · 2018: 8 · 2017: 8 · 2016: 4 · 2015: 2 · 2014: 5 · 2013: 2
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Applied and Environmental Microbiology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Immunology and Microbiology › Microbiology › Escherichia coli research studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- Escherichia coli Nissle 1917, azurin, tumor-targeting bacteria, B16 melanoma, 4T1 breast cancer, tumor growth inhibition, lung metastasis, neutrophils, lymphocytes, inflammation, bacterial drug delivery, cancer therapy, recombinant protein expression
- MeSH terms
- Animals, Antineoplastic Agents, Azurin, Disease Models, Animal, Escherichia coli, Female, Genetic Engineering, Lung Neoplasms, Mammary Neoplasms, Experimental, Melanoma, Experimental, Mice, Inbred BALB C, Plasmids, Drug Delivery Systems, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Escherichia coli Nissle 1917 Targets and Restrains Mouse B16 Melanoma and 4T1 Breast Tumors through Expression of Azurin Protein. https://app.cochat.ai/papers/10.1128/aem.01390-12
- The paper
- Zhang, Y., Zhang, Y., Xia, L., Zhang, X., Ding, X., Yan, F., & Wu, F. (2012). Escherichia coli Nissle 1917 Targets and Restrains Mouse B16 Melanoma and 4T1 Breast Tumors through Expression of Azurin Protein. Applied and Environmental Microbiology. https://doi.org/10.1128/aem.01390-12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.